MedTrace Logo

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2026-04-14

No results posted yet for this study

Summary

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Conditions

Interventions

DRUG

Ziftomenib

Oral administration

DRUG

Fludarabine

Intravenous infusion

DRUG

Idarubicin

Intravenous infusion

DRUG

Cytarabine

Intravenous Infusion

DRUG

Gilteritinib

Oral administration

BIOLOGICAL

Granulocyte colony-stimulating factor

Subcutaneous injection

Sponsors & Collaborators

  • Kura Oncology, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2026-08-31
Completion
2027-08-31
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06001788 on ClinicalTrials.gov